Local pharma producer Antibiotice is planning a significant investment in the research, development, and production of critical medicines, with a proposed RON 376.8 million.
Ceres Pharma, a Belgian pharmaceutical group, has announced the official completion of the integration process between its Romanian subsidiaries, Dacia Plant and Viva Pharma.
Novartis has over 550 employees in Romania and operates a manufacturing unit in the country.
Turnover was approximately RON 231 million in the first nine months of the year.
Opening of STADA production and supply-chain hub in Turda, Romania, strengthens European security of supply with more than 150 million packs of medicines per year.
Electro-Alfa International, a Romanian electrical equipment manufacturer, has announced plans for an Initial Public Offering (IPO) on the Bucharest Stock Exchange (BVB).
Global life sciences M&A activity increased by 81% in 2025 to $240 billion, driven by Big Pharma's large-scale deals, despite fewer overall transactions. The surge reflects companies prioritising innovations ready for launch as they face widening growth gaps.
Romania's Ministry of Finance will conduct its first public offering of Fidelis government bonds for 2026 between January 16 and 23 on the Bucharest Stock Exchange. This marks the 32nd offering since the Fidelis program resumed in July 2020.
Romania's final electricity consumption fell by 0.7% in the first 11 months of 2025 compared to the same period in 2024, according to data published by the National Institute of Statistics (INS).
Romania has the second-lowest consumer prices in the European Union, with costs 36% below the EU average in 2024, according to new Eurostat data released in December 2025.